Interpace Biosciences, Inc.
IDXG
$0.95
$0.077.35%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.91% | 21.91% | 274.38% | 294.73% | 515.44% |
| Total Depreciation and Amortization | 12.17% | -10.95% | -38.45% | -53.28% | -73.33% |
| Total Amortization of Deferred Charges | -- | 85.71% | -60.71% | -- | -100.00% |
| Total Other Non-Cash Items | -46.55% | -5.21% | -45.39% | -38.89% | -57.07% |
| Change in Net Operating Assets | 66.57% | 20.79% | -79.75% | -279.51% | -235.35% |
| Cash from Operations | 5.98% | 40.77% | 128.60% | 22.62% | 93.93% |
| Capital Expenditure | 49.72% | -64.16% | -95.84% | -86.38% | -69.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | 49.72% | -4,384.21% | -1,596.00% | -906.90% | 14.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -19.51% | -34.15% | -132.14% | -124.00% | -64.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -43.75% | -43.75% | -43.75% | -43.75% | 70.37% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.04% | 93.04% | 93.56% | 93.56% | -- |
| Cash from Financing | 22.80% | 13.75% | -25.79% | -15.40% | -154.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 76.36% | 50.42% | 41.95% | -53.16% | -128.58% |